477 related articles for article (PubMed ID: 10156942)
21. Market watch: upcoming market catalysts in Q1 of 2010.
Rosenthal J
Nat Rev Drug Discov; 2010 Jan; 9(1):11. PubMed ID: 20043022
[No Abstract] [Full Text] [Related]
22. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
23. Pharmaceutical manufacturers ... leaving tradition behind and forging new managed care alliances.
Barnett AA
State Health Care Am; 1995; ():41-6. PubMed ID: 10168072
[No Abstract] [Full Text] [Related]
24. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Alván G
Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
[No Abstract] [Full Text] [Related]
25. Researchers left to guess at outcomes of most cancer clinical trials.
Twombly R
J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
[No Abstract] [Full Text] [Related]
26. Good clinical practices.
McGirl GN
Qual Assur; 1994 Jun; 3(2):126-30. PubMed ID: 7804627
[No Abstract] [Full Text] [Related]
27. Quality assurance operations: good clinical practices.
Castellion AW
Drug Inf J; 1983; 17(1):25-9. PubMed ID: 10262248
[TBL] [Abstract][Full Text] [Related]
28. Biotech's next big blowup?
Stires D
Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033
[No Abstract] [Full Text] [Related]
29. Food and Drug Administration public hearing on the draft guidance for exception from informed consent requirements for emergency research: testimony of Novo Nordisk.
Weiskopf RB;
Acad Emerg Med; 2007 Apr; 14(4):e71-3. PubMed ID: 17322571
[No Abstract] [Full Text] [Related]
30. Growing pains for biopharmaceuticals.
Ashton G
Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
[No Abstract] [Full Text] [Related]
31. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
Falit BP
Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
[No Abstract] [Full Text] [Related]
32. Sending pharma better signals.
Avorn J
Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
[No Abstract] [Full Text] [Related]
33. Auditing clinical research data: objectives, applications and results.
Justice RL
Drug Inf J; 1983; 17(1):31-8. PubMed ID: 10262249
[TBL] [Abstract][Full Text] [Related]
34. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
35. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
36. Market watch: upcoming market catalysts in Q1 2013.
Inui E
Nat Rev Drug Discov; 2013 Jan; 12(1):12. PubMed ID: 23274459
[No Abstract] [Full Text] [Related]
37. [Clinical drug research in Denmark--as effective, harmless and cheap as possible].
Højgaard L
Ugeskr Laeger; 1994 Feb; 156(6):784-6. PubMed ID: 8016979
[No Abstract] [Full Text] [Related]
38. India's drug tests.
Padma TV
Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
[No Abstract] [Full Text] [Related]
39. Patients, physicians, and clinical trials: the other side of the coins.
Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
[No Abstract] [Full Text] [Related]
40. Market watch: Upcoming market catalysts in Q3 2013.
Roybal D
Nat Rev Drug Discov; 2013 Jul; 12(7):496. PubMed ID: 23812261
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
